Status:
RECRUITING
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous ...
Eligibility Criteria
Inclusion
- Individuals age ≥18 years
- Diagnosis of Chronic Kidney Disease (CKD) stage 3-5 \[estimated glomerular filtration rate \≤60 mL/min/1.73m2\]
- Receiving care at NYU Nephrology outpatient practice
- Able to provide informed consent
Exclusion
- Primary ANS disorders (e.g., Parkinson's disease)
- Arrhythmias
- Implantable cardioverter-defibrillator (ICD) or pacemaker (PPM) precluding assessment of HRV (e.g., chronic atrial fibrillation)
- On maintenance dialysis (HD)
- Epilepsy
- Symptomatic bradycardia
- Presence of an implantable defibrillators
- Presence of a permanent pacemaker
- Unable to consent
- Incarcerated individuals
- Pregnant individuals
Key Trial Info
Start Date :
October 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2029
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06927024
Start Date
October 15 2025
End Date
January 31 2029
Last Update
December 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016